Zealand Pharma (ZLDPF) Price & Analysis

Compare

166 Followers

ZLDPF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$47.71 - $140.10

Previous CloseN/A

Volume19.00

Average Volume (3M)397.00

Market Cap

$4.62B

Enterprise Value$9.26B

Total Cash (Recent Filing)$8.54B

Total Debt (Recent Filing)$394.64M

Price to Earnings (P/E)4.5

Beta1.56

Next Earnings

Nov 13, 2025

EPS Estimate

-1.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)16.47

Shares Outstanding71,343,800

10 Day Avg. Volume819

30 Day Avg. Volume397

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap2.00

Enterprise Value/Revenue166.19

Enterprise Value/Gross Profit177.96

Enterprise Value/Ebitda-8.33

Forecast

1Y Price Target

$104.89

Price Target Upside61.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Zealand Pharma News

Zealand Pharma Reports Strong H1 2025 Results

Zealand Pharma A/S ( ($ZLDPF) ) has released its Q2 earnings. Here is a breakdown of the information...

13d ago

ZLDPF Upcoming Earnings Report: What to Expect?

Zealand Pharma A/S (ZLDPF) is scheduled to report 2nd quarter earnings on 08/14/2025, before the market opens. Regarding...

16d ago

Zealand Pharma initiated with an Overweight at Wells Fargo

Wells Fargo analyst Cerena Chen initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 650...

1M ago

Zealand Pharma’s Petrelintide Trial: A Potential Game-Changer in Obesity Treatment?

Parexel International (($PRXL)), Zealand Pharma A/S (($ZLDPF)), Zealand Pharma (($ZEAL)) announced an update on their ongoing clinical study....

2M ago

PRXL

ZEAL

Zealand Pharma initiated with an Overweight at Barclays

Barclays analyst Yihan Li initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 560 price...

2M ago

Zealand Pharma initiated with an Outperform at BNP Paribas Exane

BNP Paribas Exane analyst Kirsty Ross-Stewart initiated coverage of Zealand Pharma (ZLDPF) with an Outperform rating and DKK...

2M ago

Zealand Pharma price target lowered to DKK 850 from DKK 1,050 at Berenberg

Berenberg lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 850 from DKK 1,050 and keeps...

2M ago

Zealand Pharma announces results from 28-week Phase 1b trial of dapiglutide

Zealand Pharma (ZLDPF) announced topline clinical results from Part 2 of a Phase 1b multiple ascending dose trial,...

2M ago

Zealand Pharma appoints Johnson as Chief Development Officer

Zealand Pharma (ZLDPF) announces the appointment of Steven Johnson as Chief Development Officer. Steven will join the executive...

3M ago

Zealand Pharma’s Earnings Call: Growth Amid Challenges

Zealand Pharma A/S (($DK:ZEAL)) has held its Q1 earnings call. Read on for the main highlights of the...

4M ago

Zealand Pharma’s Strategic Partnership Fuels Growth

Zealand Pharma A/S ( ($ZLDPF) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

Zealand Pharma appoints Utpal Singh as CSO

Zealand Pharma (ZLDPF) announces the appointment of Utpal Singh as Chief Scientific Officer. Utpal will join the executive...

4M ago

LLY

Zealand Pharma launches long-term incentive programs for board of directors

Zealand Pharma (ZLDPF) announces the implementation of long-term incentive programs for 2025 for Zealand Pharma’s Board of Directors,...

4M ago

Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750...

5M ago

ZLDPF FAQ

What was Zealand Pharma’s price range in the past 12 months?

Zealand Pharma lowest stock price was $47.71 and its highest was $140.10 in the past 12 months.

What is Zealand Pharma’s market cap?

Zealand Pharma’s market cap is $4.62B.

When is Zealand Pharma’s upcoming earnings report date?

Zealand Pharma’s upcoming earnings report date is Nov 13, 2025 which is in 77 days.

How were Zealand Pharma’s earnings last quarter?

Zealand Pharma released its earnings results on Aug 14, 2025. The company reported $16.473 earnings per share for the quarter, missing the consensus estimate of $17.052 by -$0.579.

Is Zealand Pharma overvalued?

According to Wall Street analysts Zealand Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zealand Pharma pay dividends?

Zealand Pharma does not currently pay dividends.

What is Zealand Pharma’s EPS estimate?

Zealand Pharma’s EPS estimate is -1.27.

How many shares outstanding does Zealand Pharma have?

Zealand Pharma has 71,343,800 shares outstanding.

What happened to Zealand Pharma’s price movement after its last earnings report?

Zealand Pharma reported an EPS of $16.473 in its last earnings report, missing expectations of $17.052. Following the earnings report the stock price went up 2.496%.

Which hedge fund is a major shareholder of Zealand Pharma?

Currently, no hedge funds are holding shares in ZLDPF

Company Description

Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Zealand Pharma (ZLDPF) Earnings & Revenues

Historic Earnings Reports

ZLDPF Company Deck

ZLDPF Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Zealand Pharma's earnings call was predominantly positive, highlighting strong partnerships, a robust financial position, and promising advancements in their obesity management programs. While there are some challenges, such as manufacturing delays and exchange rate losses, these are outweighed by the strategic developments and financial strength of the company.View all ZLDPF earnings summaries

ZLDPF Stock 12 Month Forecast

Average Price Target

$104.89

▲(61.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","99":"$99","142":"$142","77.5":"$77.5","120.5":"$120.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":141.04244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$141.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.3392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$62.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,77.5,99,120.5,142],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.75,64.15711076923077,70.56422153846154,76.97133230769231,83.37844307692308,89.78555384615385,96.19266461538461,102.59977538461538,109.00688615384615,115.41399692307692,121.82110769230769,128.22821846153846,134.63532923076923,{"y":141.04244,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.75,61.37615384615385,65.0023076923077,68.62846153846154,72.25461538461539,75.88076923076923,79.50692307692307,83.13307692307691,86.75923076923077,90.38538461538462,94.01153846153846,97.6376923076923,101.26384615384615,{"y":104.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.75,58.10301538461538,58.45603076923077,58.809046153846154,59.162061538461536,59.515076923076926,59.86809230769231,60.22110769230769,60.57412307692307,60.92713846153846,61.280153846153844,61.63316923076923,61.986184615384616,{"y":62.3392,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":92.98,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.51,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >